- Email: [email protected]
Vaccine composition for preventing diseases caused by viruses — envelope glycoprotein purification, hybridoma construction for monoclonal antibody secretion, application as vaccine
Patent Reports
Production of hepatitis B virus surface antigen and prem~ace antigen in Saccharomyces cerevisiae for use as vaccine Kitasato Res. Inst. Jpn 2055 086, 10 March 1987 A recombinant plasmid is constructed by integrating hepatitis B virus surface antigen (HBsAg) or presurface antigen gene into a plasmid vector able to replicate in both Escherichia coli and Saccharomyces cerevisiae and carrying the yeast galactokinase (EC 2.7.1.6) promoter region as well as a selectable marker gene. The HBsAg gene is expressed under the control of the galactokinase promoter. The recombinant plasmid is used to transform a tryptophan auxotrophic yeast strain. The transformed yeast is cultured under conditions such that the galactokinase promoter is not inhibited by the presence of galactose. The cultured cells are subjected to bacteriolysis, and HBsAg or the presurface antigen are recovered. The HBsAg is useful as a vaccine for hepatitis B. 106-87 Pseudorabies virus protein produced from recombinant DNA and used to produce vaccine and in diagnosis Upjohn World 8702 058; 9 April 1987 A new recombinant DNA molecule comprises a DNA sequence coding for a polypeptide displaying pseudorabies virus (PRV) glycoprotein gp50, gp63 or gI immunogenicity, the DNA sequence being operatively linked to an expression control sequence. The PRV glycoprotein or immunogenic fragment can be used to prepare a vaccine for pigs, sheep, cattle and goats. The gI and gp63 polypeptides can be used as diagnostic agents to distinguish between animals vaccinated with commercial vaccines and those infected with virulent virus. Production comprises isolating PRV genomic DNA from PRV Rice stain isolated from the cytoplasm of infected Vero cells and constructing a DNA library using phage ~gtll. X PRV phages are screened following plating on an Escherichia coli lawn, using a labelled antigen/antibody probe technique. Positive clones are used to transfrom E. coli hosts to produce phage k PRV stocks which can then be used to transform E. coli K95 for production of the desired virus proteins. 107-87
ologous proteins in a microorganism and a methionine codon followed by DNA encoding at least one antigenic determinant of human influenza haemagglutinin (HIH), where transcription of the DNA in a transformant is under the control of the POS and where the DNA lacks the sequence of the prepetide of HIH. Preferably, POS comprises a lac operon or a trp operon. The determinant may be e.g. amino acids 1-396 of HIH protein fused via a methionine to the first 1005 animo acids of the [)-galactosidase (EC 3.2.1.23) of the lac operon. A bacterial plasmid (pHA2-29) was constructed containing the structural gene for the haemagglutinin of the A/WSN/33 stain (HONI) of human influenza virus. A synthetic primer was used to prepare a double-stranded DNA which was inserted into the PstI site of pBR322. DNA coding for the haemagglutinin prepeptide was replaced with an AUG (methionine codon). The expression products in e.g. Escherichia coli are microbially produced, recovered and purified to levels required for use in vaccines. 109-87 Preparation of immmtopnic complex containing ant~ens with hydrophobic domains obtained by e.g. recombinant DNA technology with addition of lipids to prevent formation of aggregates; application to e.g. vaccine production and
d~nom Morein B World 8702 250; 23 April 1987
110--87
New gene coding for the protein of infectious-bronchitis virus useful in the production of peptide or protein for use in fowl vaccine Duphar Eur. 221 609; 13 May 1987
111-87
Vaccine compotition for preventing diseases caused by viruses - envelope glycoprotetn purification, hybrldoma conm-net~n for monodonul antibody secretion, xpplicoflon as vaccine Res. Corp. N.Y. Eur. 222 415; 25 May 1987
112-87
Human T-lymphotropic retrovirus HTLV-HI culture for use in AIDS vaccine and antibody detection
Immlmok~k~ ¢oml~itians including a paptide and osmium or ruthenium tetruxtde- vaccine develot~ent
US Dept Health Human Serv. US 4652 599; 24 March 1987
Nat. Res. Develop. Corp. US 4661 346; 28 April 1987
A process is described for the continuous production of HTLV-III virus and comprises infecting high susceptible permissive cells consisting of a neoplastic aneuploid T-cell line with the virus (the cells preserve the capacity for growth after infection), growing the cells under suitable conditions and recovering the virus. The virus obtained is of use in the production of AIDS virus and for antibody detection. 108-87
Dental vaccine for inhibiting periodentitis using antigen isolated from the phi of an oral micxoorgantkm e.g. Actinomyces viscosus, Actinomyces naeslindii,Act~,~bacillus actinomycem comitans or Bacteroides gingivalus
Microbial expression of human influenza haemagintinin proteins with DNA lacking the sequence of the prepaptide of Imemagginfinin protein; use as vaccine
Kitasato-Res. Inst. US 4661 350; 28 April 1987
113-87
114-87
Univ. Calif.; Genetech US 4659 699; 21 April 1987
New membrane protein containing ~ vesicle composition with c l i e n t ~ of protein in large vesicles with retained biological activity e s p c c ~ y for use in vaccines; liposome
A replicable microbial expression vehicle contains a promoter-operator sequence (POS) capable of expressing heter-
Mannino R J US 4663 161; 5 May 1987
322
Vaccine, Vol. 5, December 1987
115-87
Production of hepatitis B virus surface antigen and prem~ace antigen in Saccharomyces cerevisiae for use as vaccine Kitasato Res. Inst. Jpn 2055 086, 10 March 1987 A recombinant plasmid is constructed by integrating hepatitis B virus surface antigen (HBsAg) or presurface antigen gene into a plasmid vector able to replicate in both Escherichia coli and Saccharomyces cerevisiae and carrying the yeast galactokinase (EC 2.7.1.6) promoter region as well as a selectable marker gene. The HBsAg gene is expressed under the control of the galactokinase promoter. The recombinant plasmid is used to transform a tryptophan auxotrophic yeast strain. The transformed yeast is cultured under conditions such that the galactokinase promoter is not inhibited by the presence of galactose. The cultured cells are subjected to bacteriolysis, and HBsAg or the presurface antigen are recovered. The HBsAg is useful as a vaccine for hepatitis B. 106-87 Pseudorabies virus protein produced from recombinant DNA and used to produce vaccine and in diagnosis Upjohn World 8702 058; 9 April 1987 A new recombinant DNA molecule comprises a DNA sequence coding for a polypeptide displaying pseudorabies virus (PRV) glycoprotein gp50, gp63 or gI immunogenicity, the DNA sequence being operatively linked to an expression control sequence. The PRV glycoprotein or immunogenic fragment can be used to prepare a vaccine for pigs, sheep, cattle and goats. The gI and gp63 polypeptides can be used as diagnostic agents to distinguish between animals vaccinated with commercial vaccines and those infected with virulent virus. Production comprises isolating PRV genomic DNA from PRV Rice stain isolated from the cytoplasm of infected Vero cells and constructing a DNA library using phage ~gtll. X PRV phages are screened following plating on an Escherichia coli lawn, using a labelled antigen/antibody probe technique. Positive clones are used to transfrom E. coli hosts to produce phage k PRV stocks which can then be used to transform E. coli K95 for production of the desired virus proteins. 107-87
ologous proteins in a microorganism and a methionine codon followed by DNA encoding at least one antigenic determinant of human influenza haemagglutinin (HIH), where transcription of the DNA in a transformant is under the control of the POS and where the DNA lacks the sequence of the prepetide of HIH. Preferably, POS comprises a lac operon or a trp operon. The determinant may be e.g. amino acids 1-396 of HIH protein fused via a methionine to the first 1005 animo acids of the [)-galactosidase (EC 3.2.1.23) of the lac operon. A bacterial plasmid (pHA2-29) was constructed containing the structural gene for the haemagglutinin of the A/WSN/33 stain (HONI) of human influenza virus. A synthetic primer was used to prepare a double-stranded DNA which was inserted into the PstI site of pBR322. DNA coding for the haemagglutinin prepeptide was replaced with an AUG (methionine codon). The expression products in e.g. Escherichia coli are microbially produced, recovered and purified to levels required for use in vaccines. 109-87 Preparation of immmtopnic complex containing ant~ens with hydrophobic domains obtained by e.g. recombinant DNA technology with addition of lipids to prevent formation of aggregates; application to e.g. vaccine production and
d~nom Morein B World 8702 250; 23 April 1987
110--87
New gene coding for the protein of infectious-bronchitis virus useful in the production of peptide or protein for use in fowl vaccine Duphar Eur. 221 609; 13 May 1987
111-87
Vaccine compotition for preventing diseases caused by viruses - envelope glycoprotetn purification, hybrldoma conm-net~n for monodonul antibody secretion, xpplicoflon as vaccine Res. Corp. N.Y. Eur. 222 415; 25 May 1987
112-87
Human T-lymphotropic retrovirus HTLV-HI culture for use in AIDS vaccine and antibody detection
Immlmok~k~ ¢oml~itians including a paptide and osmium or ruthenium tetruxtde- vaccine develot~ent
US Dept Health Human Serv. US 4652 599; 24 March 1987
Nat. Res. Develop. Corp. US 4661 346; 28 April 1987
A process is described for the continuous production of HTLV-III virus and comprises infecting high susceptible permissive cells consisting of a neoplastic aneuploid T-cell line with the virus (the cells preserve the capacity for growth after infection), growing the cells under suitable conditions and recovering the virus. The virus obtained is of use in the production of AIDS virus and for antibody detection. 108-87
Dental vaccine for inhibiting periodentitis using antigen isolated from the phi of an oral micxoorgantkm e.g. Actinomyces viscosus, Actinomyces naeslindii,Act~,~bacillus actinomycem comitans or Bacteroides gingivalus
Microbial expression of human influenza haemagintinin proteins with DNA lacking the sequence of the prepaptide of Imemagginfinin protein; use as vaccine
Kitasato-Res. Inst. US 4661 350; 28 April 1987
113-87
114-87
Univ. Calif.; Genetech US 4659 699; 21 April 1987
New membrane protein containing ~ vesicle composition with c l i e n t ~ of protein in large vesicles with retained biological activity e s p c c ~ y for use in vaccines; liposome
A replicable microbial expression vehicle contains a promoter-operator sequence (POS) capable of expressing heter-
Mannino R J US 4663 161; 5 May 1987
322
Vaccine, Vol. 5, December 1987
115-87